Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr;204(2):389-396.
doi: 10.1007/s10549-023-07204-7. Epub 2024 Jan 4.

Targeted axillary dissection: worldwide variations in clinical practice

Michalis Kontos #  1 , Prodromos Kanavidis #  2 , Thorsten Kühn  3 , Yazan Masannat  4   5 , Bahadir Gulluoglu  6 ; TAD Study Group
Collaborators, Affiliations

Targeted axillary dissection: worldwide variations in clinical practice

Michalis Kontos et al. Breast Cancer Res Treat. 2024 Apr.

Abstract

Purpose: Targeted axillary dissection (TAD) for the axillary staging of clinically node-positive (cN +) breast cancer patients converting to clinically node negative post neoadjuvant chemotherapy (NAC), has gained popularity due to its minimal false negative rate and low arm morbidity. The aim of this study is to shed more light on the variation in the clinical practice globally in terms of indications and perceived limitations of TAD.

Methods: A panel of expert breast surgeons constructed a structured questionnaire comprising of 18 questions and asked surgeons worldwide for their opinions and routine practice on TAD. The questionnaire was electronically distributed and answers were collected between May 1st and August 1st 2022.

Results: Responses included 137 entries from 36 countries. Of them, 73.7% consider TAD for cN + patients planned to receive NAC. Among them, the greatest number of respondents (45%) perform the procedure for tumours up to T3, whereas 27% regardless of T-stage. The majority (42%) perform TAD on patients with 1-3 positive nodes and only 30% consider TAD when matted nodes are present. HER2 positive and Triple Negative subtypes are more likely to undergo TAD than Luminal A and B (86%, 79.1%, 39.5%, and 62.8%, respectively). Maximum acceptable lymph node burden is median 3 nodes for any subtype with a tendency to accept more positive nodes for Triple Negative.

Conclusion: This study demonstrates the differences in current practice regarding TAD as well as the fact that the biology of the tumour heavily affects the method of axillary staging.

Keywords: Axillary staging; Breast cancer; Preoperative chemotherapy; Sentinel node biopsy; Targeted axillary dissection; Tumour subtypes.

PubMed Disclaimer

References

    1. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S, Senkus E, on behalf of the ESMO Guidelines Committee. Early breast cancer, ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. https://www.esmo.org/content/download/284512/5623447/1/Clinical-Practice.... Accessed 6 Jan 2023
    1. Friedrich M, Kühn T, Janni W, Müller V, Banys-Paluchowski M, Kolberg-Liedtke C, Jackisch C, Krug D, Albert US, Bauerfeind I et al (2021) AGO recommendations for the surgical therapy of the axilla after neoadjuvant chemotherapy: 2021 update. Geburtshilfe Frauenheilkd 81:1112–1120. https://doi.org/10.1055/a-1499-8431 - DOI - PubMed - PMC
    1. NCCN guidelines, Version 4.2022, June 21, 2022. Available online: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 6 Jan 2023
    1. Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, Bedrosian I, Hobbs BP, DeSnyder SM, Hwang RF et al (2016) Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol 34:1072–1078. https://doi.org/10.1200/jco.2015.64.0094 - DOI - PubMed - PMC
    1. Gasparri ML, de Boniface J, Poortmans P, Gentilini O, Kaidar-Person O, Paluchowski-Banys M, Di Micco R, Niinikoski L, Murawa D, Bonci EA et al (2022) Axillary surgery after neoadjuvant therapy in initially node-positive breast cancer: international EUBREAST survey. Br J Surg 10:857–863. https://doi.org/10.1093/bjs/znac217 - DOI

LinkOut - more resources